saturation at which nucleation occurs is determined largely by the size of the nanodroplets present (10) .
Could the precritical clusters observed by Gebauer et al. also be the result of stabilization of calcium carbonate clusters by another species present as an impurity? This mechanism would provide a basis for stabilizing precritical clusters in a free-energy minimum and does not contradict classical nucleation theory. Such impurities are ubiquitous and virtually impossible to eliminate from any solution. The results of Gebauer et al. may thus reflect the mechanism of nucleation of calcium carbonate in "real" systems. Nucleation could then occur by coalescence of the precritical clusters to give ACC, which will subsequently crystallize to a more stable crystalline polymorph. The latter mechanism is consistent with the observations of Gebauer et al., who show that ACC is the first phase precipitated after nucleation.
The idea that nucleation of calcium carbonate may proceed via an aggregation mechanism is highly topical. The past decade has seen great progress in understanding crystallization processes, and it is now well recognized that single-crystal growth (as distinct from nucleation) often occurs via the aggregation of small precursor units rather than by addition of ions or molecules to a nucleus (11) . Cluster species have also been observed before nucleation in saturated solutions of compounds such as sodium chloride (2), urea (12) , and glycine (3), and there have been suggestions that clustering can determine which polymorph is formed (13) . However, none of these even remotely approach the size or stability of the clusters observed by Gebauer et al. Further investigation of precritical clusters and their role in the crystallization of calcium carbonate, and indeed other compounds, is eagerly anticipated. D eciphering the sequence of the human genome and the subsequent cataloging of common human DNA sequence variation marked a paradigm shift in human genetics. These resources, together with advances in cost-effective genotyping technologies, enabled the design of genomewide association studies for the unbiased discovery of commonly occurring DNA sequence variations called single-nucleotide polymorphisms (SNPs) that are preferentially associated with a disease or other clinical trait (1) . Although genome-wide association studies have uncovered disease-associated SNPs, identifying actual disease-causing variantsand gaining deep insights into how those variants generate the underlying molecular pathophysiology-have so far yielded only modest results. This has led to criticisms of the genome-wide association approach for investigating the etiologies of common diseases (2) . However, this assessment may be premature. On page 1839 of this issue, Sankaran et al. (3) show how genome-wide association findings can lead to a detailed understanding of disease mechanisms and be used to ascertain novel therapeutic targets.
Previous genome-wide association studies conducted in independent populations have identified SNPs in three chromosomal loci that are associated with varying expression levels of human fetal hemoglobin (HbF) (4) (5) (6) . HbF is a clinically important quantitative trait because elevated concentrations reduce the severity of sickle cell disease and β-thalassemia, disorders caused by different mutations in the human β-globin gene (7). Normally, HbF predominates in the fetus but declines to very low amounts postnatally due to repression and activation of the γ-globin and β-globin genes, respectively. The "switch" that controls these reciprocal changes in globin gene expression has been intensively investigated, but the molecular basis of this developmental process remains largely unknown. As reported by Sankaran et al., functional studies motivated by recent HbF genome-wide association findings have provided a major breakthrough in understanding the hemoglobin switching problem.
One of the SNPs associated with elevated HbF expression is found in an intron (noncoding region) of the BCL11A gene on human chromosome 2 (see the figure) . BCL11A encodes a protein that represses transcription in the B lymphoid lineage (8).
Sankaran et al. hypothesized that BCL11A might repress expression of the γ-globin gene, with expression or activity of this repressor correlating inversely with HbF production both during normal development and in individuals of different genotypes at the BCL11A locus. They first determined that BCL11A is expressed as two long isoforms, encoded by alternatively spliced messenger RNAs (mRNAs), in primary adult erythroblasts. By contrast, only shorter variants of BCL11A are found in human embryonic erythroleukemia cells and in primary human fetal liver cells, both of which express high amounts of HbF. Moreover, the genotype at the BCL11A SNP that affects HbF production influences expression of mRNAs encoding the long isoforms in lymphoblastoid cell lines: High expression of BCL11A mRNA corresponds to homozygosity for the allele associated with low HbF production; low mRNA expression corresponds to homozygosity for the allele associated with high HbF production; and SNP heterozygotes express intermediate amounts of mRNA (see the figure) . If the association between the BCL11A SNP and the expression level of this gene in lymphoblasHuman genetic studies have led to the identification of a transcriptional regulator that could serve as a therapeutic target for adult hemoglobin disorders.
toid cell lines also applies to erythroid cells, then the causative SNP either has a non-tissue-specific effect on transcription, or it acts at the posttranscriptional level, an issue that remains to be resolved.
Although the results are consistent with the long isoforms of BCL11A functioning to suppress HbF production in a dose-dependent manner, they do not distinguish between a direct effect on γ-globin gene expression and an indirect effect on the kinetics of erythropoiesis that might cause cells containing HbF to be overproduced (9) . Additional findings of Sankaran et al. argue strongly in favor of the former model. For example, BCL11A was found to interact with multiple components of the nucleosome remodeling and histone deacetylase (NuRD) complex, which functions in transcriptional repression (10) , as well as with GATA-1 and FOG-1, the major activating transcription factor and cofactor, respectively, of the erythroid lineage (11) . Further, RNA interference specific for BCL11A in primary erythroid progenitors increased γ-globin mRNA expression and HbF production without inducing a generalized effect on cellular differentiation or altering expression of known globin gene transcription factors. Finally, chromatin immunoprecipitation revealed that BCL11A binds to multiple regions within the human β-globin locus that control silencing of the γ-globin gene (7).
Thus, BCL11A plays an important role in fetal-to-adult hemoglobin switching during normal erythropoiesis, and its expression in adult erythroid cells affects the amount of HbF produced. This raises questions about what controls the stage-specific shift between the long and short BCL11A isoforms, and the molecular mechanism by which BCL11A represses γ-globin gene expression. It is also not clear which genetic variant in BCL11A sets the expression level of this gene, nor how it functions in this capacity. Higherresolution studies of BCL11A chromatin occupancy, functional characterization of the putative cisregulatory elements containing these binding sites, and sequencing of the entire region of BCL11A that is in linkage disequilibrium with the SNP used to discover its relevance to HbF expression are needed to address these questions.
The findings of Sankaran et al. also have potential consequences for developing new therapies to treat sickle cell disease and other hemoglobinopathies. The inverse correlation between BCL11A and HbF expression, combined with the known ameliorative effect of HbF on the pathophysiology of sickle cell disease and β-thalassemia, suggests that inhibition of BCL11A expression or function could be an effective treatment for these disorders. The study also illustrates that, when experiments are appropriately designed, the initial findings of genomewide association studies can be successfully followed up at a functional level.
T o convert the encoded genetic information from eukaryotic DNA into proteins, base sequences of genes are first transcribed into RNA by RNA polymerase II. To produce functional RNA molecules, dozens of accessory factors are needed to define the proper locations for RNA polymerase II to begin and end transcription. Although we have some basic knowledge about how these factors work, it is still not possible to take a eukaryotic genome sequence and accurately predict what RNA species it will produce. Recent efforts to map and sequence "transcriptomes" have only increased the challenge by revealing a much more complex set of RNAs than expected, including many that do not produce proteins. The latest surprise, described in four papers in this issue (1) (2) (3) (4) , is a new class of transcripts that initiate near the expected transcription start sites upstream of protein-encoding sequences. However, these RNAs are short, present at low abundance, and often occur in the direction opposite to that of the proteincoding region (see the figure) . It remains to be seen whether these RNAs have a function, but their existence challenges our simplistic models about how the DNA sequences known as "promoters" define transcription start sites.
In current textbook models, promoters comprise two interacting parts. Basal promoter elements bind accessory transcription initiation factors that position RNA polymerase II in the right place and direction. Enhancer elements bind regulatory factors Transcription just got noisier with the discovery of short RNAs that are synthesized at or near DNA regions that also initiate full-length RNAs. From SNP to mechanism and potential therapy. Hemoglobin genes on human chromosome 11 are differentially expressed in the embryo, fetus, and adult. A SNP in the BCL11A gene is associated with varying amounts of fetal hemoglobin in human populations. Because there is an inverse correlation between BCL11A and fetal hemoglobin expression, inhibiting BCL11A is a potential therapy for adult hemoglobinopathies. LCR HSS: locus control region hypersensitive sites. The asterisk indicates a DNA region that, when deleted, is associated with increased fetal hemoglobin production.
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